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Multidrug-resistant tuberculosis (MDR-TB) has been 
a growing concern among health authorities worldwide 
because the treatment for MDR-TB is long-term, costly 
and complex. In addition, MDR-TB increases the rate 
of hospital admissions and TB-related mortalities (Ros-
setti et al. 2002).
In 2008, it was estimated that there were 440,000 
MDR-TB cases and 150,000 deaths worldwide; 3.6% of 
the new TB cases were likely to be associated with mul-
tidrug-resistant strains of Mycobacterium tuberculosis 
(WHO 2010a, b).
In Brazil, there are few population-based studies that 
have estimated the incidence rate of MDR-TB (Telles et 
al. 2005). The available data show a range from 1-8% of 
all new cases and 3-13% of previously treated TB pa-
tients (Brito et al. 2010, Santos et al. 2010). 
The factors that are associated with MDR-TB in-
clude prior treatment, cavitary pulmonary TB, treat-
ment failure, inadequate drug regimens, illicit drug use, 
human immunodeficiency virus (HIV) infection, hos-
pitalisation two years prior to TB diagnosis, diabetes 
and alcohol dependence (Kritski et al. 1997, Telles et al. 
2005, Faustini et al. 2006).
In 2010, the annual TB incidence rate in the state of 
São Paulo (SP) was estimated to be approximately 40.5 
per 100,000 inhabitants-year (MS 2011), which is slight-
ly above the national average (38.0 per 100,000 inhabit-
ants-year). However, 53% of new cases were clustered in 
10 of 647 municipalities, notably in the city of Santos, 
which had an incidence rate that was twice as high as the 
average rate in SP (SES 2011).
Between 2000-2004, 2,176 cases of pulmonary TB 
were reported in Santos. Of these cases, 23% of the pa-
tients had a past history of TB. The mean prevalence of 
TB-HIV co-infection was 16% and the average cure and 
treatment dropout rates were 71% and 12%, respectively 
(Coelho et al. 2009). These data highlight the challenges 
faced by the Brazilian National Tuberculosis Control 
Programme (NTCP) and the high prevalence of risk fac-
tors for MDR-TB in the city of Santos.
Monitoring the extent of and trends in MDR-TB is a 
priority for the NTCP. Surveillance systems for MDR-
TB were implemented in Brazil in 2000 and were based 
on periodic national surveys and MDR-TB screening of 
high-risk groups (MS 2007). The current study aimed to 
estimate the incidence of MDR-TB in the city of Santos, 
describe the profile of TB drug resistance in risk groups 
and examine the adherence to the recommended guide-
lines for MDR-TB screening.
PATIENTS, MATERIALS AND METHODS
A descriptive study was conducted in the city of San-
tos. Santos is located within the metropolitan area of 
Baixada Santista and, in 2010, had an estimated popula-
tion of 420,000; 99% of the inhabitants live in the urban 
area (MPOG 2010). Santos is a priority city for the NTCP, 
as it has one of the highest incidence rates of TB in SP; 
Santos had a TB incidence rate of 85.0 per 100,000 in-
habitants-year in 2010 (SES 2011). The study population 
consisted of patients who were diagnosed and treated for 
pulmonary TB between 2000-2004 and living in Santos 
from 1 January 2000-31 December 2004.
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Monitoring the extent of and trends in multidrug-resistant tuberculosis (MDR-TB) is a priority of the Brazil-
ian National Tuberculosis Control Programme. The current study aimed to estimate the incidence of MDR-TB, 
describe the profile of TB drug resistance in risk groups and examine whether screening for MDR-TB adhered to 
the recommended guidelines. A descriptive study that examined diagnosed cases of pulmonary TB was conducted 
in the city of Santos, Brazil, between 2000-2004. Of the 2,176 pulmonary TB cases studied, 671 (30.8%) met the 
criteria for drug sensitivity testing and, of these cases, 31.7% (213/671) were tested. Among the tested cases, 9.4% 
were resistant to one anti-TB drug and 15% were MDR. MDR was observed in 11.6% of 86 new TB cases and 17.3% 
of 127 previously treated cases. The average annual incidence of MDR-TB was 1.9 per 100,000 inhabitants-years. 
The extent of known MDR-TB in the city of Santos is high, though likely to be underestimated. Our study therefore 
indicates an inadequate adherence to the guidelines for MDR-TB screening and suggests the necessity of alterna-
tive strategies of MDR-TB surveillance.
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Cases of pulmonary TB were defined as individuals 
of both sexes aged 15 years or older who had clinical 
symptoms consistent with TB and confirmed by at least 
one of the following criteria: smear microscopy or cul-
ture with isolation of M. tuberculosis or confirmed by 
evidence of TB by clinical examination and X-rays with 
findings suggestive of pulmonary cavity. 
MDR-TB cases were defined as individuals who, in 
addition to meeting the pulmonary TB case definition, had 
strains of M. tuberculosis that were resistant to at least both 
isoniazid (INH) and rifampicin (RMP) (SBPT 2009).
For the MDR-TB screening with drug sensitivity 
testing (DST), the NTCP guidelines included testing of 
high-risk TB patients who exhibited the following char-
acteristics: presence of TB-HIV co-infection, suspected 
drug resistance due to treatment dropout, treatment fail-
ure, TB relapse or contact with an MDR-TB strain, sus-
pected primary drug resistance and inclusion in a high-
risk group, such as health providers, the homeless and 
institutionalised populations (MPOG 2010). 
For participation in the study, patients had to meet 
the DST criteria described above, exhibit pulmonary TB 
with cultured isolation of M. tuberculosis, be undergoing 
DST, diagnosis and treatment of TB in the city’s health 
services during the study period and be reported to the 
TB surveillance system of Baixada Santista.
The exclusion criteria included patients that were 
infected with nontuberculous mycobacteria or patients 
whose information could not be confirmed in accord 
with the study criteria.
The data sources used in the study were the TB Sur-
veillance System of Baixada Santista, the Adolfo Lutz 
Institute, the Santos Regional Laboratory and the Cen-
tral Laboratory. The Brazilian Institute of Geography 
and Statistics was used to collect the demographic data.
The following variables were studied: sociodemo-
graphic characteristics, current and past history of TB 
and aspects related to TB diagnosis, treatment and co-
morbidities.
Laboratory techniques - Sputum samples were di-
gested and decontaminated using the Petroff method 
and were inoculated into Lowenstein-Jensen medium. 
The samples were subsequently incubated at 37ºC for 
60 days and examined weekly. The cultures were scored 
negative if there was no growth within 60 days. The iso-
lated mycobacteria were identified based on their bio-
chemical properties (MS 2008).
Drug resistance was tested by the resistance ratio 
method for INH, RMP, streptomycin and ethambutol. 
For pyrazinamide, resistance was tested by the pyrazi-
namidase test (Jenkins et al. 1985).
Data analysis - The database obtained from the TB sur-
veillance system was formatted for use with Epi Info ver-
sion 6.4 software. The data were first analysed for consis-
tency and duplicates and cases that did not meet the study 
criteria were excluded. The laboratory data were compared 
against the Adolfo Lutz Institute database and were cor-
rected and completed as needed. Analyses were performed 
with the Statistical Package for Social Sciences version 
15 and the variables were reclassified when appropriate.
For descriptive data analysis and group comparisons, 
the chi-square and Fisher’s exact tests were used for cat-
egorical variables and the Kruskal-Wallis test was used 
for continuous variables.
The patients with pulmonary TB who met the 
screening criteria for DST were first compared with 
the patients who did not met the criteria; subsequently 
the patient who met the screening criteria and under-
go DST were compared with the patients who met the 
screening criteria and did not undergo DST. Finally, the 
drug resistance profiles of the patients undergoing DST 
were analysed, comparing the drug resistance profiles 
among the new TB cases with patients who had a past 
history of TB.
The average annual incidence rate of drug resistance 
for the period between 2000-2004 was calculated by di-
viding the number of patients with any type of resistance 
by the number of individuals in the population that were 
aged 15 years or older and were living in Santos at the 
midpoint of the study; next, the resulting number was 
divided by five. Based on reports in the literature, the 
prevalence of the risk factors for MDR-TB was estimat-
ed in patients with strains that were sensitive to all the 
drugs tested and in patients with different drug resis-
tance profiles.
The current study was approved by the Research 
Ethical Committee of the Adolfo Lutz Institute (proto-
col 25/06).
RESULTS
Based on the study criteria, a total of 2,176 cases of 
pulmonary TB were identified in the city of Santos be-
tween January 2000-December 2004. Among the cases, 
30.8% (671/2,176) met the criteria for DST (i.e., had risk 
factors for MDR-TB) and 31.7% (213/671) of these indi-
viduals actually underwent testing. Of those undergoing 
DST, 59.6% (127/213) had a prior history of TB treatment 
(Figure). The proportion of patients actually undergoing 
testing among all those who met the criteria for DST re-
mained constant during the study period. 
There were no significant differences in the sociode-
mographic characteristics of patients who met and pa-
tients who did not meet the criteria for DST. However, 
a higher rate of supervised treatment (67.1% vs. 61.7%, 
p = 0.017) and hospitalisation during treatment (42.8% 
vs. 30.4%, p < 0.0001) and a lower prevalence of dia-
betes (5.4% vs. 9.8%, p = 0.001) were observed among 
patients who met the criteria for DST. However, in the 
same group, the cure rate was lower (64% vs. 86%, p 
< 0.001) and the proportion of unfavourable outcomes 
[dropout, death due to TB or acquired immune deficien-
cy syndrome (AIDS) and treatment failure] was higher 
(36% vs. 14%, p < 0.001).
The data available on the 671 patients who met the 
criteria for DST showed that 61.8% (400/647) had a past 
history of TB and 50.8% (332/653) were co-infected with 
HIV. Among those with a past history of TB, 60.2% 
(240/399) were treatment dropouts (Table I). 
In a comparison between patients undergoing 
(213/671) and patients not undergoing DST (468/671), 
the patients undergoing DST showed a lower proportion 
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of TB-HIV co-infection (39.2% vs. 56.3%, p < 0.003), a 
higher proportion of patients with cavitary pulmonary le-
sions (31.9% vs. 15.1%, p < 0.001) and a higher proportion 
of patients that changed treatment regimens (12.2% vs. 
3.4%, p < 0.0001). Regarding the outcomes, there were 
no differences between the groups (Table I). However, 
the proportion of supervised treatment was higher among 
those undergoing DST (77.3% vs. 62.4%, p < 0.0001).
Of the patients with pulmonary TB who underwent 
DST (n = 213), 73.7% (157/213) were sensitive to all of 
the drugs tested, 9.4% (20/213) were resistant to one drug 
and 15% (32/213) were MDR. Of all of the patients who 
underwent DST (n = 213), 86 (40.4%) were new cases, of 
which 74.4% (64/86) were sensitive to all the drugs test-
ed, 11.6% (10/86) were resistant to one drug and 11.6% 
(10/86) were primary MDR-TB cases. In contrast, of the 
127/213 (59.6%) cases with a prior history of TB treat-
ment, 73.3% (93/127) were sensitive to all the drugs test-
ed, 7.8% (10/127) were resistant to one drug and 17.3% 
(22/127) were acquired MDR-TB cases (Table II).
A comparison of the primary MDR-TB cases with 
the acquired MDR-TB cases showed a higher cure rate in 
the former group (70% vs. 31.8%, p = 0.008) and this rate 
was slightly lower than that observed in patients who did 
not meet the criteria for DST.
Among the MDR-TB cases, most were males (78%; 
25/32) between the ages of 20-49 (79%) with a median 
age of 39.2 years. TB-HIV co-infection was present in 
22% (7/32) of the cases and 68.7% (22/32) of the patients 
had a past history of TB. A change in the treatment regi-
men was reported in 47% (14/30) of the cases and su-
pervised treatment was provided in 75% (24/32) of the 
cases. Among these patients, 43.8% (14/32) were cured, 
31.2% (10/32) dropped out of the TB treatment, 15.6% 
(5/32) died from TB, 3.1% (1/32) died from other causes 
and 6.4% (2/32) had treatment failure. 
A comparison of the prevalence of the risk factors for 
TB drug resistance between the cases that were sensi-
tive to all the drugs tested and the cases that exhibited 
MDR-TB showed that the latter had a lower proportion 
of TB-HIV co-infection (21.9% vs. 43.9%, p < 0.05), a 
higher proportion of individuals that changed treatment 
regimens (43.7% vs. 3.8%, p < 0.05) and a higher propor-
tion of cavitary pulmonary lesions (46.9% vs. 24.8%, p 
< 0.05) (Table III).
Based on the cases identified in the study, the av-
erage annual incidence rate of MDR-TB in the city of 
Santos was 1.9 per 100,000 inhabitants-year. For fe-
males, the incidence rate was 0.75 per 100,000-year in 
females and for males, the rate was 3.26 per 100,000 in-
habitants-year in males. The annual incidence rates for 
of primary and acquired MDR-TB were 0.6 and 1.3 per 
100,000 inhabitants-year, respectively. The average an-
nual incidence rates of primary and acquired resistance 
to one or more TB drugs were 1.4 and 1.9 per 100,000 
inhabitants-year, respectively.
Flowchart of the study population and its distribution according to characteristics of patient samples undergoing DST, Santos, Brazil, 2000-
2004. MDR: multidrug resistant.
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DISCUSSION
The city of Santos is characterised by an almost 
exclusively urban population with a high population 
density and favourable socioeconomic indicators. It is 
among the three largest metropolitan areas in SP and 
is the largest port in Latin America. Santos ranks fifth 
among Brazilian cities with the highest Human De-
velopment Index (0.871) and has an extensive network 
of public health services. According to the Brazilian 
Health Policy, Santos provides universal free access to 
TB diagnosis and treatment (MPOG 2010). However, 
the characteristics of TB in this city are similar to those 
observed in hyperendemic areas (Coelho et al. 2009), 
with programmatic indicators potentially associated 
with higher risk for occurrence of MDR-TB.
The results of the current study corroborate the poor 
programmatic indicators found in Santos during the 
study period. One-third of TB cases reported between 
2000-2004 had risk factors for MDR-TB, which is a pro-
portion that is similar to that reported in a low-income 
community with high TB rates in the city of São Paulo 
(Telles et al. 2005), but much higher than that found 
in the state of Mato Grosso do Sul, in central-western 
TABLE I
Characteristics of patients with pulmonary tuberculosis (TB) who met the criteria 
for tuberculosis drug susceptibility testing (DST), Santos, Brazil, 2000-2004
Characteristics
Underwent DST
Total
 (n = 671)
n (%) p
Yes
(n = 213)
n (%)
No
(n = 458)
n (%)
Gender 0.23
Female 57 (27.4) 143 (31.2) 200 (29.8) -
Male 156 (73.2) 315 (68.8) 471 (70.2) -
Age (years)
15-19 4 (1.9) 10 (2.2) 14 (2.1) 0.76
20-49 167 (78.4) 368 (80.3) 535 (79.7) -
50 or more 42 (19.7) 80 (17.5) 122 (18.2) -
Schooling 0.28
Up to 7 years 61 (34.7) 162 (44.6) 223 (41.4) -
8 years or more 115 (65.3) 201 (55.4) 316 (58.6) -
Alcohol dependence 0.14
No 166 (83) 379 (87.7) 545 (86.2) -
Yes 34 (17) 53 (12.3) 87 (13.8) -
HIV infection < 0.0003
No 127 (60.8) 194 (43.7) 321(49.2) -
Yes 82 (39.2) 250 (56.3) 332 (50.8) -
Past history of TB 0.25
No 86 (40.4) 161 (37.1) 247 (38.2) -
Yes 127 (59.6) 273 (62.9) 400 (61.8) -
Outcome of prior TB treatment 0.57
Cure 45 (35. 7) 114 (41.8) 159 (39.8) -
Dropout 81 (64. 3) 159 (58.2) 240 (60.2) -
Relapse 0.27
No 169 (82) 300 (76.0) 499 (78) -
Yes 37 (18) 104 (24.0) 141 (22) -
Cavitary pulmonary lesions < 0.0001
No 128 (68.1) 331 (84.9) 459 (79.4) -
Yes 60 (31.9) 59 (15.1) 119 (20.6) -
Treatment regimen < 0.0001
Unchanged 173 (87.8) 422 (96.6) 595 (93.8) -
Changed 24 (12.2) 15 (3.4) 39 (6.2) -
Treatment completion
Cure 127(67.2) 255 (62.3) 382 (63.9) 0.24
Unfavourable outcomea 63 (32.8) 154 (37.7) 217 (36.1) -
a: dropout, deaths from TB and acquired immune deficiency syndrome, treatment failure; HIV: human immunodeficiency virus. 
Inconsistencies between total patients studied and total variables are due to missing information.
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Brazil (Marques et al. 2010). Notably, only 30% of the 
high-risk patients were screened for MDR-TB, suggest-
ing an operational challenge to adhering to the NTCP 
guidelines. According to the 2007 national data, the 
challenges in Santos are similar to those generally pres-
ent nationwide (Kritski 2010). These results highlight 
the need to increase directly observed treatment short-
course coverage and provide ongoing training for the 
teams that are responsible for TB control. In addition, in 
medium-sized and large cities, the team should include 
an epidemiologist who will monitor performance indi-
cators and compliance with the programme’s guidelines 
and recommendations.   
The incidence rate of MDR-TB in Santos is concern-
ing not only because it is notably high (at least 1.5% of all 
pulmonary TB cases in the city), but because it is likely 
to be an underestimate, as it represents only the cases 
that were identified in one-third of the risk groups. The 
remaining two-thirds of the cases shared features with 
those cases undergoing DST, including most risk factors 
for MDR-TB (Kritski et al. 1997, Telles et al. 2005, Faus-
tini et al. 2006) and unfavourable outcomes. 
We found that there was a higher incidence of pri-
mary and acquired resistance to INH or RMP and pri-
mary and acquired MDR-TB than what was reported 
in the preliminary data from the Second National Sur-
vey of Anti-Tuberculosis Drug Resistance, which was 
conducted in seven Brazilian states, as well as in other 
recent studies in Brazil (Ferrazoli et al. 2000, Telles 
et al. 2005, Souza et al. 2006, Kritski 2010, Marques 
et al. 2010) and in developing countries (WHO 2010a). 
In contrast with other Brazilian studies (Telles et al. 
2005, Kritski 2010, Marques et al. 2010), the prevalence 
of primary and acquired resistance is quite similar in 
Santos, indicating that MDR-TB is a more serious 
problem in the city. Primary drug resistance is a sen-
sitive indicator for evaluating the performance of the 
NTCP because the higher the primary drug resistance, 
the greater the risk of spreading resistant strains in the 
community (WHO 2010b). 
The cases of MDR-TB that were identified in San-
tos were similar to those described in other studies con-
ducted in Brazil (Telles et al. 2005, Dalcomo et al. 2007, 
Vieira et al. 2007, Brito 2010, Santos 2010) in that the 
cases involved predominantly working-age males and 
two-thirds of the cases had a prior history of TB treat-
ment. Supervised treatment was lower than that recom-
mended by the NTCP. The cure rate was low (40%), but 
it was higher among the primary MDR-TB cases (70%). 
The proportion of unfavourable outcomes was notably 
high and one-fifth of the patients died. In light of this 
scenario and bearing in mind that these proportions are 
likely to be an underestimate, TB drug resistance should 
be a priority for the NTCP and will require strategies 
specifically designed for hyperendemic TB areas.
The patients with MDR-TB had a higher prevalence 
of cavitary pulmonary lesions and clinically suspected 
drug resistant TB than the patients with strains that were 
sensitive to all the drugs. These findings are plausible, 
as certain groups (Barroso et al. 2003) consider cavitary 
pulmonary lesions to be a risk factor for MDR-TB. 
The prevalence of HIV infection was higher among 
patients with strains that were sensitive to all the drugs 
tested than in patients with MDR-TB. Such a finding 
deserves comment. The prevalence of TB-HIV co-in-
fection in MDR-TB cases in our study was higher than 
that reported in other studies conducted in SP (Melo 
et al. 2003, Telles et al. 2005), but was similar to that 
found in another study in the metropolitan area of Santos 
(Rozman et al. 2007). These inconsistencies may be ex-
plained by the fact that Santos is a port city and has one 
of the highest rates of HIV/AIDS in SP (SES 2010).
Although several studies showed an association be-
tween TB-HIV co-infection and MDR-TB (Faustini et 
al. 2006, Haar et al. 2007), thereby supporting the NTCP 
recommendation for routine DST for all HIV-infected 
patients, no evidence of an association was found in our 
study. This finding corroborates other studies that have 
TABLE II
Drug resistance profiles of isolates from 213 patients 
with pulmonary tuberculosis (TB) confirmed by isolation 
of Mycobacterium tuberculosis and who underwent drug 
susceptibility testing, Santos, Brazil, 2000-2004
Characteristics
New cases
(n = 86)
n (%)
Prior TB 
treatment
(n = 127)
n (%)
Total
(n = 213)
n (%)
Sensitive to all drugs 64 (74.4) 93 (73.2) 157(73.7)
Resistant to any drug 22 (25.6) 34 (26.7) 56 (26.3)
IHN 19 (22.1) 31 (24.4) 50 (23.5)
RMP 11 (12.8) 24 (18.9) 35 (16.4)
PZA 6 (7) 14 (11) 20 (9.4)
SM 5 (5.8) 6 (4.7) 11 (5.2)
EM 3 (3.5) 7 (5.5) 10 (4.7)
Resistant to one drug 10 (11.6) 10 (7.8) 20 (9.4)
IHN 7 (8.1) 7 (5.5) 14 (6.6)
RMP 1 (1.2) 2 (1.6) 3 (1.4)
SM 1 (1.2) - 1 (0.5)
EM 1 (1.2) 1 (0.8) 2 (0.9)
MDR 10 (11.6) 22 (17.3) 32 (15)
INH + RMP 4 (4.7) 6 (4.7) 10 (4.7)
INH + RMP + PZA 2 (2.3) 8 (6.3) 10 (4.7)
INH + RMP + PZA + SM 3 (3.5) 1 (0.8) 4 (1.9)
INH + RMP + PZA + EM 1 (1.2) 3 (2.4) 4 (1.9)
INH + RMP + PZA + SM + EM - 1 (0.8) 1 (0.5)
INH + RMP + SM - 1 (0.8) 1 (0.5)
INH + RMP + SM + EM - 2 (1.6) 2 (0.9)
Other drug resistance profiles 2 (2.3) 2 (1.6) 4 (1.9)
INH + PZA - 1 (0.8) 1 (0.5)
INH + EM + SM - 1 (0.8) 1 (0.5)
INH + SM 1 (1.2) - 1 (0.5)
INH + EM 1 (1.2) - 1 (0.5)
EM: ethambutol; INH: isoniazide; MDR: multidrug resistant; 
PZA: pyrazinamide; RMP: rifampicin; SM: streptomycin; TB: 
tuberculosis.
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been conducted in Brazil (Barroso et al. 2003, Telles et 
al. 2005) and is supported by a recent systematic litera-
ture review (Suchindran et al. 2009).
When interpreting the results of our study, several 
limitations of the study need to be acknowledged. The 
study was based on secondary data, which can often 
be incomplete and only data from a third of the at-risk 
population for TB drug resistance were analysed. De-
spite these limitations, our results are consistent with 
the literature and allowed us to estimate the extent and 
examine the profile of TB drug susceptibility among the 
high-risk MDR-TB patients. Such data can be used to 
develop targeted control strategies.
The findings of this study support at least three ma-
jor recommendations: (i) to develop strategies to im-
prove the surveillance of MDR-TB in hyperendemic ar-
eas (e.g., a citywide sentinel surveillance system), (ii) to 
investigate whether TB-HIV co-infection is associated 
with MDR-TB in Brazil and (iii) given the high rates of 
primary drug resistance found, patients and their house-
hold contacts should be monitored for two years after 
completing treatment and a strategy should be developed 
to contact TB patients who have dropped out of their 
treatment protocol.
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Relapse 2 (8.3) 6 (18.7) 8 (14.3) 29 (18.5) 37 (17.4)
HIV infection 6 (25.) 7 (21.9)d 13 (23.2) 69 (43.9) d 82 (39.2)
Clinically suspected resistancec 4 (16.7) 14 (43.7)d 17 (30.3) 6 (3.8) d 48 (22.5)
Past history of TB 12 (50) 22 (68.7) 36 (64.3) 93 (59.2) 127 (59.6)
Health provider 1 (4.2) - 1 (1.8) 2 (1.3) 3 (1.4)
Alcohol dependence 4 (16.7) 8 (25) 12 (21.4) 22 (14) 36 (16.9)
Supervised treatment 18 (75) 24 (75) 42 (75) 121 (77.1) 163 (76.5)
Diabetes 1 (4.1) 3 (9.4) 4 (7.1) 5 (3.4) 9 (4.2)
Cavitary pulmonary lesions 6 (25) 15 (46.9)d 21 (37.5) 39 (24.8) d 60 (28.2)
a: resistant to at least one of five drugs tested or other type of resistance [drug resistance profile other than multidrug resistant 
(MDR) or resistant to one drug]; b: resistant to at least isoniazid and rifampicin whether or not associated with other drugs; c: 
patients whose treatment regimen was changed; d: p < 0.05; HIV: human immunodeficiency virus.
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